DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ginkgo Bioworks Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.07−0.20 (-1.95%)
Close on Oct 19, 2026
- Market cap
- $625.29M
- P/E (TTM)
- –
- Dividend yield
- –
Ginkgo Bioworks Holdings, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $20.16M | $19.47M | – | – | $39.13M | $38.23M | – | – | – | – | – | – | 100.0% | -48.5% |
| Biosecurity | – | – | – | $9.46M | $10.47M | $10.09M | – | $13.96M | $20.00M | $10.06M | $7.78M | $18.25M | – | – |
| Cell Engineering and Biosecurity | – | – | – | – | – | – | – | $89.05M | $56.21M | $37.94M | – | $55.43M | – | – |
| Cell Engineering | – | – | $26.00M | $29.38M | $39.13M | $38.23M | $34.79M | $75.09M | $36.21M | $27.89M | $26.98M | $37.18M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biosecurity | – | – | -$4.05M | -$4.88M | -$4.82M | -$5.19M | -$9.75M | -$6.21M | -$3.44M | -$11.22M | -$11.68M | -$1.19M | – |
| Cell Engineering and Biosecurity | – | – | -$21.32M | -$41.62M | -$14.75M | -$36.77M | -$47.89M | -$11.36M | -$86.47M | -$103.47M | -$61.14M | -$97.52M | – |
| Cell Engineering | – | – | -$17.27M | -$36.74M | -$9.94M | -$31.59M | -$38.14M | -$5.15M | -$83.02M | -$92.25M | -$49.47M | -$96.33M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | – | – | – | – | $10.47M | $10.09M | $9.06M | $13.96M | $20.00M | $10.06M | $7.78M | $11.76M | – | – |
| Product | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $6.50M | – | – |
| Cell Engineering | – | – | – | – | $39.13M | $38.23M | $34.79M | $75.09M | $36.21M | $27.89M | $26.98M | $37.18M | – | – |
| Biosecurity | – | – | – | $9.46M | – | – | – | $13.96M | – | – | – | – | – | – |
| Cell Engineering | – | – | – | $29.38M | – | – | – | $75.09M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ginkgo Bioworks's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.